Fuji Pharma Co., Ltd.
Notice Regarding Completion of Exercise of the 2nd Series Stock Acquisition Rights Issued by Third-Party Allotment
On March 11, 2026, all 16,500 units of the 2nd series stock acquisition rights of Fuji Pharmaceutical Industries Ltd. were exercised, completing fundraising of 3.3 billion yen.
Key Figures
- Number of Stock Acquisition Rights Issued: 16,500 units
- Funds Raised Through Exercise of Stock Acquisition Rights: 3,300,000,000 yen
- Total Number of Outstanding Shares: 26,541,100 shares
AI要約
Completion of Exercise of Stock Acquisition Rights
Fuji Pharmaceutical Industries Ltd. announced that all 16,500 units of the 2nd series stock acquisition rights issued on August 5, 2024, with Nomura Securities Co., Ltd. as the allottee, were fully exercised as of March 11, 2026. As a result, fundraising of 3.3 billion yen was realized, and the total number of outstanding shares reached 26,541,100 shares, with capital stock amounting to 5,555,919,505 yen.
Impact on Shareholders and Future Outlook
The exercise of these stock acquisition rights led to the issuance of new shares, which may cause potential dilution of shareholders' equity. For more details, please refer to the "Notice Regarding Issuance of 1st through 3rd Series Stock Acquisition Rights by Third-Party Allotment" published on July 18, 2024. There is no information in this document regarding future capital use or business development impact, so these remain unknown.
